Generic antiretroviral drugs in developing countries: friends or foes?

Zucman, Davida; Camara, Seydoua; Gravisse, Jéromea; Dimi, Svetlanea; Vasse, Marca; Goudjo, Abdonb; Choquet, Marionc; Peytavin, Gillesc

doi: 10.1097/QAD.0000000000000170
Research Letters

Although second-line generic antiretroviral drugs are of great value in developing countries, there are concerns regarding their quality. We studied a generic Lopinavir/ritonavir (200/50 mg; Arga-L, India) marketed in the Republic of Congo but not prequalified by WHO. Despite adequate quantitative and qualitative drug content, Arga-L had a bio-availablility of 10% compared with Kaletra. To avoid selection of drug-resistant HIV, rigorous pharmacological monitoring of generic drugs not prequalified by WHO must be a priority.

aHôpital FOCH, Suresnes, France

bFrance Expertise Internationale, Paris, France

cPharmaco-Toxicology Department, Hôpital Bichat, Paris, France.

Correspondence to Dr David Zucman Hôpital Foch, Service de médecine interne 92150 Suresnes France. E-mail: d.zucman@hopital-foch.org

Received 23 September, 2013

Revised 28 November, 2013

Accepted 28 November, 2013

Copyright © 2014 Wolters Kluwer Health, Inc.